Cargando…
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
Prurigo nodularis (PN) is a chronic inflammatory skin disease with intensely pruritic nodules. The LIBERTY-PN PRIME and PRIME2 phase 3 trials enrolled adults with PN with ≥20 nodules and severe itch uncontrolled with topical therapies. Dupilumab, a fully human monoclonal antibody, blocks the shared...
Autores principales: | Yosipovitch, Gil, Mollanazar, Nicholas, Ständer, Sonja, Kwatra, Shawn G., Kim, Brian S., Laws, Elizabeth, Mannent, Leda P., Amin, Nikhil, Akinlade, Bolanle, Staudinger, Heribert W., Patel, Naimish, Yancopoulos, George D., Weinreich, David M., Wang, Sheldon, Shi, Genming, Bansal, Ashish, O’Malley, John T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202800/ https://www.ncbi.nlm.nih.gov/pubmed/37142763 http://dx.doi.org/10.1038/s41591-023-02320-9 |
Ejemplares similares
-
Recalcitrant prurigo nodularis treated successfully with dupilumab
por: Rambhia, Pooja H., et al.
Publicado: (2019) -
Immunotargets and Therapy for Prurigo Nodularis
por: Labib, Angelina, et al.
Publicado: (2022) -
Simultaneous treatment of Samter triad and prurigo nodularis with dupilumab
por: Bloomstein, Joshua D., et al.
Publicado: (2021) -
Dupilumab for the treatment of prurigo nodularis: A systematic review
por: Cao, Peng, et al.
Publicado: (2023) -
Effective Treatment of Prurigo Nodularis with Dupilumab: A Case Report
por: Liu, Chuan, et al.
Publicado: (2022)